Reviewing Genmab A/S (NASDAQ:GMAB) and Bolt Biotherapeutics (NASDAQ:BOLT)

Bolt Biotherapeutics (NASDAQ:BOLT) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Profitability

This table compares Bolt Biotherapeutics and Genmab A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
Genmab A/S	16.97%	13.67%	6.42%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Bolt Biotherapeutics and Genmab A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1	1	2	0	2.25
Genmab A/S	0	1	10	1	3.00

Bolt Biotherapeutics presently has a consensus price target of $14.50, suggesting a potential upside of 130.16%. Genmab A/S has a consensus price target of $53.61, suggesting a potential downside of 0.85%. Given Bolt Biotherapeutics’ higher possible upside, equities analysts clearly believe Bolt Biotherapeutics is more favorable than Genmab A/S.

Insider and Institutional Ownership

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Bolt Biotherapeutics and Genmab A/S”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70 million	1.58	-$33.38 million	($16.44)	-0.38
Genmab A/S	$3.72 billion	9.07	$963.00 million	$1.17	46.21

Genmab A/S has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Bolt Biotherapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.

Summary

Genmab A/S beats Bolt Biotherapeutics on 11 of the 15 factors compared between the two stocks.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.

About Genmab A/S

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.